Third Harmonic Bio
Clinical-stage company developing a first-in-class, highly selective, oral KIT inhibitor for treatment of severe allergy and inflammation.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
* | N/A | $185m | IPO |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Third Harmonic Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for inflammatory diseases affecting the skin, respiratory system, and gastrointestinal tract. The company focuses on advancing THB335, a highly selective, oral small molecule wild type KIT inhibitor, aimed at treating chronic urticaria, severe asthma, and other mast cell-mediated inflammatory conditions. Third Harmonic Bio operates within the biopharmaceutical market, primarily serving patients suffering from these chronic conditions. The business model revolves around the research, development, and eventual commercialization of its proprietary treatments. Revenue generation is expected through the successful development and market introduction of its therapeutic products. The company is committed to improving patient outcomes by providing innovative and effective treatment options.
Keywords: biopharmaceutical, inflammatory diseases, KIT inhibitor, chronic urticaria, severe asthma, mast cell, THB335, novel therapeutics, clinical-stage, targeted treatment.